Significant discrepancies exist when comparing cancer care systems in the United States and the Continent. The American model, generally characterized by market-driven website insurance and a emphasis on innovation, often leads to swift introduction of cutting-edge therapies, albeit at a significantly increased cost. On the other hand, European sys